Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670330 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
A Phase 3 study, sponsored by Scioderm.
- Terminated
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT02670330: Clinical Trial Phase 3 study, sponsored by Scioderm.
NCT02670330 is a Phase 3 study that was terminated before completion, run by Scioderm. The registered enrollment target is 152 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670330, a Phase 3 study, was terminated before completion, sponsored by Scioderm.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
Primary Outcome
TEAEs were defined as adverse events that started or worsened on or after baseline visit.
Interventions
- DRUG SD-101-6.0 cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2015-06-09 |
| Est. Completion | 2018-09-03 |
| Phase | Phase 3 |
Why NCT02670330 stopped before completion
NCT02670330 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which SD-101-6.0 cream is the first listed.
NCT02670330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02670330 about?
NCT02670330 is a clinical study titled "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa". The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
What is the current status of trial NCT02670330?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2015-06-09. Estimated completion is 2018-09-03.
What interventions are being tested in trial NCT02670330?
The interventions under investigation include: SD-101-6.0 cream (DRUG).
Who is sponsoring clinical trial NCT02670330?
This trial is sponsored by Scioderm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02670330's enrollment target sits among peer trials
152 1513th of 2000 higher than 484 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI